fda compounding semaglutide crackdown news today 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Drugmakers battle pharmacies over compounded

Retatrutide Availability & Timeline Retatrutide is expected to receive FDA approval in mid-2027 with pharmacy availability in late 2027

Being more careful and steadier with the needle seems to have helped

List price is the original price set for a medication by a manufacturer before any discounts or rebates are applied

Instead of following the standard titration schedule, where you increase your dose every four weeks until you hit the high maintenance level, microdosers stay at the lowest effective dose for months, or even take less than the starting dose

8 minutes) Beyond the Hype: Unraveling the Real Story Behind GLP-1 and Metabolic Healing Imagine waking up each morning feeling foggy, heavy, and frustrated

Retatrutide, however, wont be on the market until it completes Phase 3 and earns FDA approval